Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Shares Traded Last Trade
  22.00 1.71% 1,310.00 246,877 16:35:00
Bid Price Offer Price High Price Low Price Open Price
1,292.00 1,294.00 1,326.00 1,290.00 1,300.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 87.73 -6.57 1,077
Last Trade Time Trade Type Trade Size Trade Price Currency
18:45:02 O 179 1,310.066 GBX

Oxford Biomedica (OXB) Latest News

More Oxford Biomedica News
Oxford Biomedica Investors    Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica Forums and Chat

Date Time Title Posts
15/6/202118:33Feck off the_doctor13,943
15/6/202117:55Oxford Biomedica1,942
14/6/202114:14Truth Vs. Deception64
23/3/202119:30OXB - another over-valued stock206
23/11/202008:59OXFORD BIOMEDICA (OXB): MODERATED CHART AND DISCUSSION THREAD72,943

Add a New Thread

Oxford Biomedica (OXB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:45:021,310.071792,345.02O
16:38:561,312.891,83324,065.20O
16:28:221,310.001061,388.60O
16:02:541,311.784926,453.98O
15:57:381,310.025,02665,841.66O
View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

DateSubject
15/6/2021
09:20
Oxford Biomedica Daily Update: Oxford Biomedica Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 1,288p.
Oxford Biomedica Plc has a 4 week average price of 1,048p and a 12 week average price of 935p.
The 1 year high share price is 1,326p while the 1 year low share price is currently 701p.
There are currently 82,223,225 shares in issue and the average daily traded volume is 152,125 shares. The market capitalisation of Oxford Biomedica Plc is £1,077,124,247.50.
11/6/2021
17:21
gareth jones: Well done Professor Alan Kingsman (and his late wife, Professor Susan Kingsman), in the early years of OXB Prof. Kingsman said he thought, believed, hoped his fledgling spin out of Oxford would one day be a $(or £) billion company. We done sir, you did it! Hopefully OXB is just in the foothills of it climb to the summit. FTSE100 one day if still an independent company? No longer a laughable question. G7 Summit now says it’s time to vaccinate the World. Covax will facilitate but a hugh opportunity for OXB if they wish to get involved massively. AZN will give OXB a glowing report surely! Hopefully HMG will also push UK PLC via OXB.
31/5/2021
12:52
marcusl2: I`ll be interested to see what OXB in-license that is ready for the clinic. OXB is in a position to look for bolt-on acquisitions that complement the pipeline or enhance technology capabilities. OXB will assess partnering opportunities with academic institutions or companies and will also look at potential in-licensing opportunities that are further on in the clinic; these will likely be assets that are ready to enter the clinic. OXB has expressed a particular interest in liver indications such as haemophilia, where AAV therapies have shown proof of concept and LVVs have inherent advantages based on their ability to integrate into the host genome, potentially enabling a one-off treatment for any age. While we note the Boehringer Ingelheim partnership has moved beyond LVV, the first partnership that focuses on other vectors specifically will be a key inflection point for the company, vastly increasing its addressable market and further diversifying revenue streams. When Kymriah reaches peak royalties including FL 28 million manufacturing 18 million Add AZ and everything else then earnings could be excellent in the next few years. AXO-Lenti-PD / NA / Parkinson's / Phase I/II 2026 Peak royalties Peak manufacturing revenue (£m 106 24 . OXB-302 / NA / Cancer / Preclinical 2025 56 9 . OXB-203 / NA / Wet AMD / Preclinical 2027 117 13
28/5/2021
08:27
marcusl2: I think that work is with Beam PH. Beam Therapeutics’ next-generation technology In August 2020, Beam Therapeutics signed a development, manufacture and licence agreement (DMLA) granting it a non-exclusive licence to OXB’s LentiVector platform for application in next-generation CAR-T programmes in oncology. A three-year clinical supply agreement (CSA) is also in place for OXB to provide clinical trial material to Beam, in return for LVV development and clinical trial manufacturing supply payments. US biotech Beam Therapeutics is focused on developing precision genetic medicines utilising its proprietary base editing technology, a highly innovative next-generation CGT technology. We believe that this collaboration will enable OXB to work towards next-generation products. The pipeline is very early stage (preclinical) and focused on a range of therapeutic areas: hemoglobinopathies, oncology, liver disease, ophthalmology and the central nervous system (CNS). OXB is currently undertaking work on one preclinical asset with Beam; we note the agreement allows for the parties to initiate additional projects in the future. While OXB has not disclosed the exact details of the project it is working on, we believe the relevant product appears to be the engineered allogeneic (or off-the-shelf) CAR-T products, via multiplex editing of T-cells from healthy donors. Given the preclinical nature of Beam’s assets and its novel technologies (base editing and allogenic CAR-T), the time to market is longer than more recent deals such as that with Juno.
27/5/2021
22:15
marcusl2: Thanks Harry. While OXB has not disclosed the exact details of the project it is working on, we believe the relevant product appears to be the engineered allogeneic (or off-the-shelf) CAR-T products, via multiplex editing of T-cells from healthy donors. We therefore assume AZN will extend the vaccine supply agreement for an additional 18 months (to September 2023) and increase our forecasts for vaccine-related revenues to £87.5m (vs £15.0m previously) and £87.5m in (vs £7.0m previously) in FY21 and FY22, respectively. For the first time we include vaccine-related revenues of £55.0m in FY23. Car TCR, we expect OXB to garner more deals as one of very few CDMOs with experience developing an FDA-approved CGT. follicular lymphoma; and the data will form the basis of US and EU regulatory submissions (expected in H221). Phase III BELINDA study in first relapse DLBCL is expected in H221 Kymriah consensus sales are estimated at more than $1.1bn by 2025 Boehringer Ingelheim This new agreement highlights encouraging progress in its partnership with Boehringer Ingelheim and importantly moves beyond LVV to other vector types (undisclosed), likely adeno-associated viruses (AAV) and adenovirus. The next steps will be to enrol patients into the volume expansion cohort three, before the planned commencement of a randomised, sham-controlled portion of the study, initially expected to start enrolling patients in 2021. However, delays in CMC data and third-party fill/finish issues have caused the development of a suspension-based manufacturing process for AXO-Lenti-PD to take longer than expected. OXB has commenced manufacturing of several GMP batches for use in future clinical trials. Sio Gene Therapies now does not expect the AXO-Lenti-PD Phase II EXPLORE-PD study comparing the highest dose versus a sham surgical procedure to start enrolling patients before the end of 2021. We therefore take these timelines into account and prudently delay our AXO-Lenti-PD launch date by two years to 2026. OXB has demonstrated that its TRiP technology works in AAV and adenovirus, and the majority of its other technologies, for example SecNuc, may also be applied. Thus, OXB could attract potential partners due to its superior technologies that are also applicable to these vectors. strengthened balance sheet after the AZN vaccine deal, OXB is in a position to look for bolt-on acquisitions that complement the pipeline or enhance technology capabilities. OXB will assess partnering opportunities with academic institutions or companies and will also look at potential in-licensing opportunities that are further on in the clinic; these will likely be assets that are ready to enter the clinic. expects to both increase the number of partners and expand the number of programs with existing partners. Discussions and feasibility studies with multiple potential partners are ongoing.
27/5/2021
13:02
xia: I bought my fist set of shares at 70p somme 20 years ago. It was a lump sum of £600 and one of my first investment. Since then I have mostly been accumulating and done the all eggs in one basket thingy. I went all in to make things more interesting, with a big chunk of my savings few month before the Novartis deal. So yeah, some serious sentimental attachment and emotional ride with the share price. But today, I have started selling my holding. I need to get rid of it due to Brexit and the rules governing my account in France holding the shares before 15thn of September, and this feel strange, really strange. I have always been a lurker, first on III then on advfn and want to thanks everyone that have contributed to this thread and added massive amount of research that has allowed / help / enabled me to carry my faith in the share. For bragging rights... I'm up 400% I guess once fully unloaded, I will say a final good by to all and remove the link from my favourite. Note: my kids will take over.Both of them have Child fund trust with you can guess 1000 shares of OXB each (my daughter being champ of return with shares bought in the era of the 5p per share) :) Sorry for the long irrelevant blurb but It feels really emotional closing the door on 20 years of investment and have no where else to express it.
23/5/2021
13:37
abd009: Hi Harry, Probably more stupid than brave,talk about putting all your eggs in one basket, but then at that time you weren't able to get 25% of your pot tax free and it seemed a long time till i reached the age of 55 , I felt it was worth taking a gamble on an outsider ,which in this case eventually won the race for me. My only regret is that I had no other cash to invest outside my sipp. Any how thanks to you Marcus and other contributors it gave me strength to keep investing in oxb. But more importantly the success of oxb is in helping those who are suffering from complicated illness. I wish you all well and look forward to give my prediction for the next sweep and hopefully by then we will all have smiles on our faces when we either have been taking over by a larger company or the oxb price would have moved up to a significantly higher price. 🙏
12/5/2021
22:19
brad1: I noticed that a similar situation occurred in 2018 when there looked like a support level with the 50dma breaking the £6 high, only for the share price to retreat again to the 100dma at £5 before doubling in price to above £10. If the recent bounce off the 100 dma becomes sustained and acts as a support level then we may get to the £20 mark in a matter months. RSI was also at the mid level then before rising into overbought territory before the retracemnet. Hoping we see some good strength in share price in the coming weeks
11/5/2021
21:36
harry s truman: Jasie, I'll not pretend to understand economic policies other than at a Ladybird level, but from reading newspaper stories there seem to be 2 schools of thought:- 1) being that Japan has been throwing money at their problems for years and hasn't caused inflation. 2) that JY has been too heavy handed with US monetary policy and that the genie is out of the bottle now (the worry for us with that one being that we follow the US and not Japan). Sooner or later we find out what is what. I agree with what you say btw, but some of the people buying today won't have been alive when there were 15% mortgages so it's not in their subconscious. tim, What I've probably done here is remembered you talking about SCLP and pinned that on trovax, which is why you should never ask me to be a witness in your defence ;) What do I think about SCLP? They remind me a little of OXB early days in that there is obviously a lot of potential. The tricky part of course is predicting the fraction of the pipeline which makes it to market. If I could do that then I'd have my own jet now. I've seen the video where Cliff explains the antibody treatment using that graph with the 3 curves. It seems very compelling. I hold some but I hold much more OXB. There is no single one good share but OXB for me has been a very long term hold for reasons that I've blathered on about forever. Lots of people who owned OXB have also at some point had PRM too. Famously doc, but many others as well. I've never held PRM but I did buy into IMM for lupus when SK (another old hand here) thought that it had amazing potential. My timing with that one wasn't great as I'd sold before the huge rise, but we live and learn. I'm very comfortable having a lot of money in OXB as it makes money / pays its own way, which is more reassuring than holding a share which is 100% expectation. There is reward to be had with that risk (of the wholly expectation route) but I've had some disasters too. I'm at the age now where I'm definitely at one with Jim Slater's idea that if you hold shares in anything where you're not 100% comfortable with the risk, then at some point (ideally on a double but it doesn't have to be that much) sell your original stake and let the remainder run for free. That's a much happier place to be should trouble raise its head.
09/5/2021
16:39
blinddarts: Hi Marcus, As you know the subject was Accelerating Personalised Medicines. Leslie Southam OXB QA Manager spoke about how we scaled up and scaled out production with the FPC60 line. James Drinkwater of Franz Ziel and Peter Birch of Watson-Marlow were both very complimentary of the way OXB developed the process platform between filtration and the new fill & finish line. It sounded like OXB really impressed Franz Ziel and Watson Marlow on the novel approach. James Drinkwater also said that OXB are, whilst developing these processes, involving and training a lot of major Pharma which must also be promoting our name and expertise throughout the industry. The regulatory bodies are only now formulating new guidelines and (presumably) OXB will be at the forefront of that regulation development. (I made a huge assumption there !! :-) ) I couldn't detect any 'new' news mentioned inadvertently - but I'm sure that they are heavily coached in what they can and can't say. That's all I can think of at the moment. Many thanks for your tireless contribution to this thread, which I hope you know is much appreciated.
15/4/2021
11:55
gigabit: #13175 You are quite right about 'profits in the future'. That is fine for enthusiasts like those of us on this board but the share price is driven by the market and we are a miniscule part of that. A lot of investors, especially pension funds and the like, need income and will invest in companies delivering dividends. As has been pointed out OXB will not do that in the next few years (and it is the bottom line profit or loss that determines that not EBITDA) so that excludes those investors from buying. That leaves those interested in short term capital gain and us, the long term holders. For short termers a volatile share price is what they want so they can move in and out. We have two choices, sit on our hands or replicate their strategy. I suspect most of us prefer the first option.
Oxford Biomedica share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
OXB
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210615 19:13:01